Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Organogenesis (ORGO) had Normalized Pre-Tax Income of $-11.83M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$101.00M |
|
$-12.20M |
|
$27.63M |
|
$73.38M |
|
$113.58M |
|
$-12.58M |
|
$0.74M |
|
$-11.83M |
|
|
Normalized Pre-Tax Income |
$-11.83M |
$-9.39M |
|
$-9.39M |
|
$-9.39M |
|
$-9.39M |
|
$-12.58M |
|
$-5.92M |
|
126.85M |
|
126.85M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$260.22M |
|
$75.61M |
|
$200.91M |
|
$461.13M |
|
$65.84M |
|
$0.10M |
|
$162.05M |
|
$227.89M |
|
$233.24M |
|
$193.69M |
|
$233.24M |
|
126.85M |
|
| Cash Flow Statement Financials | |
$-52.81M |
|
$-7.26M |
|
$-2.34M |
|
$136.15M |
|
$73.73M |
|
$-62.42M |
|
$5.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.95 |
|
-- |
|
-- |
|
0.00 |
|
0.01 |
|
72.64% |
|
-12.45% |
|
-12.45% |
|
-- |
|
-11.72% |
|
-12.08% |
|
$-60.07M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
0.84 |
|
0.84 |
|
107.27 |
|
-4.03% |
|
-4.85% |
|
-2.04% |
|
-4.03% |
|
$1.84 |
|
$-0.47 |
|
$-0.42 |
|